Cyfra 21-1, a New Tumor and Cancer Detecting Test, is being studied in our laboratory.
Cyfra 21-1, a New Tumor and Cancer Detecting Test, is being studied in our laboratory.CYFRA 21-1 is a new tumor detecting test, also known as Cytokeratin fragment 19, and is one of the most specific tests to detect lung, esophageal and bladder cancers. In bronchial cancers, CYFRA 21-1 test positivity has a high rate of 85% compared to other markers such as CEA and SCC. Considering the role of tumor markers in the differentiation of malignant pleural effusions from benign ones, Cyfra 21-1 and Ca 15-3 We see that . has the highest sensitivity and specificity. The combined use of these two markers gives more decisive results. This assay is performed using the Fujirebio Diagnostics CYFRA 21-1 Enzyme Immunoassay. Results obtained with different assay methods or kits cannot be used interchangeably. The results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. A tumor marker that tests for esophageal, lung, and bladder cancers.